`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`————————————————
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`————————————————
`
`MYLAN PHARMACEUTICALS INC.
`Petitioner,
`v.
`
`ASTRAZENECA AB
`Patent Owner.
`
`————————————————
`Case No. IPR2016-01316 (6,774,122)
`Case No. IPR2016-01324 (7,456,160)
`Case No. IPR2016-01325 (8,329,680)
`Case No. IPR2016-01326 (8,466,139)1
`————————————————
`
`UPDATED MANDATORY NOTICE PURSUANT TO
`37 CFR §§ 42.8(a)(3) AND (b)(2)
`
`
`
`
`1 A word-for-word identical Notice is being filed in each proceeding.
`
`
`
`Pursuant to 37 C.F.R. §§ 42.8(a)(3) and 42.8(b)(2), Petitioners hereby
`
`identify the following litigation in which United States Patent Nos. 6,774,122,
`
`7,456,160, 8,329,680, and 8,466,139 are asserted by Patent Owner:
`
` AstraZeneca Pharmaceuticals LP et al. v. Mylan Institutional LLC,
`
`Civil Action No. 1:16-cv-04612-RMB-KMW (D.N.J.), filed July 29,
`
`2016.
`
`
`
`Dated: August 3, 2016
`
`
`
`
`
`
`
`
`
`
`/Brandon M. White/
`Brandon M. White
`Reg. No. 52,354
`Perkins Coie LLP
`700 13th St. NW, Suite 600
`Washington, D.C. 20005
`Telephone: (202) 654-6206
`E-mail: bmwhite@perkinscoie.com
`
`Attorney for Mylan Pharmaceuticals Inc.
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`
`
`The undersigned hereby certifies that the foregoing UPDATED
`
`MANDATORY NOTICE PURSUANT TO 37 CFR §§ 42.8(a)(3) AND (b)(2) was
`
`served electronically via email as follows:
`
`
`
`Patent Owners:
`
`Filko Prugo
`O’Melveny & Myers LLP
`fprugo@omm.com
`
`Marc Pensabene
`O’Melveny & Myers LLP
`mpensabene@omm.com
`
`Caitlin Hogan
`O’Melveny & Myers LLP
`chogan@omm.com
`
`
`Kevin Murray
`O’Melveny & Myers LLP
`Kmurray2@omm.com
`
`/Brandon M. White/
`Brandon M. White
`
`Attorney for Mylan Pharmaceuticals Inc.
`
`
`
`Dated: August 3, 2016